Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
5
×
boston top stories
genentech
5
×
life sciences
national blog main
national top stories
roche
5
×
san francisco blog main
cancer
san francisco top stories
boston
deals
eli lilly
indiana blog main
indiana top stories
new york blog main
avapritinib
blueprint medicines
boulder/denver blog main
boulder/denver top stories
cancer immunotherapy
celgene
detroit blog main
detroit top stories
fda
investing
medullary thyroid cancer
national
new york top stories
non-small cell lung cancer
novartis
pfizer
pralsetinib
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
What
cancer
drug
approval
blueprint
fda
latest
medicines
ret
roche
acquire
address
agreed
alzheimer’s
annual
approves
big
billion
bio
breast
broad
cancer's
candidate
carries
certain
clinical
companies
conference
confidence
currently
data
designed
didn’t
different
esmo
european
fail
foundation
gain
gene
genentech
Language
unset
Current search:
genentech
×
roche
×
" boston blog main "
×
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
ESMO ’18: Precision Meds, Breast, Lung, and More from the Cancer Front
@xconomy.com
5 years ago
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine